{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:21:53Z","timestamp":1787721713130,"version":"build-2784847793"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004480","name":"Natural Science Foundation of Shanxi Province","doi-asserted-by":"publisher","award":["202304041101043, 202203021221257"],"award-info":[{"award-number":["202304041101043, 202203021221257"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Elderly AML (Acute Myeloid Leukemia) patients exhibit increased mortality owing to chemotherapy-induced myelosuppression. Umbilical cord blood (UCB) contains hematopoietic stem\/progenitor cells and a spectrum of regenerative cytokines that actively promote hematopoietic regeneration. We investigated whether umbilical cord blood (UCB) infusion enhances hematopoietic recovery in elderly AML patients who experience chemotherapy-induced myelosuppression during post-chemotherapy supportive care.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively analyzed 95 elderly patients with AML in complete remission (CR1) who previously developed grade III\u2013IV chemotherapy-induced myelosuppression. The control group (n=60) received standard supportive care, including granulocyte colony-stimulating factor (G-CSF), blood product transfusions, and antibiotic therapy. The experimental group (n = 35) underwent infusion of unrelated umbilical cord blood (UCB; CD34\n                      <jats:sup>+<\/jats:sup>\n                      cells \u22652\u00d710\n                      <jats:sup>6<\/jats:sup>\n                      \/kg) within 24 hours post - chemotherapy, along with standard supportive care.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Neutrophil recovery duration (\u22651.0\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L) was reduced in the UCB group (16 VS 23 days, P&amp;lt;0.01). Platelet recovery (\u226550\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L) was also shorter (13 days vs. 19 days, P&amp;lt;0.01), though hemoglobin recovery (\u226570 g\/L) did not differ significantly (18 days vs. 21 days, P&amp;gt;0.05). The incidence of grade III\u2013IV infections decreased to 31.43% (vs. 55.00%, P&amp;lt;0.05), that of bleeding events decreased to 11.43% (vs. 33.33%, P&amp;lt;0.05), that of transfusion-related allergic reactions decreased to 17.14% (vs. 26.67%, P&amp;lt;0.05), and chemotherapy delay\/reduction rates decreased to 14.29% (vs. 35.00%, P&amp;lt;0.05). The overall survival (OS) was significantly longer in the UCB group, and the 2-year relapse-free survival (RFS) was higher (P&amp;lt;0.05). The most common adverse events were transfusion-related (e.g., rash and transient fever). Graft-versus-host disease (GVHD) was not observed in the UCB group.\n                    <\/jats:p>\n                    <jats:p>\n                      These findings indicate that UCB infusion enhances hematopoietic recovery, reduces complications, and improves the survival of elderly patients with AML after chemotherapy, likely through the synergistic effects of CD34\n                      <jats:sup>+<\/jats:sup>\n                      cells and cytokines.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1867070","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:52:27Z","timestamp":1787719947000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Umbilical cord blood infusion enhances hematopoietic recovery and improves survival in elderly AML patients with chemotherapy-induced myelosuppression: a retrospective study"],"prefix":"10.3389","volume":"16","author":[{"given":"Yimin","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Hematology, First Hospital of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuye","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Hematology, First Hospital of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, First Hospital of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenya","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Hematology, First Hospital of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Hematology, First Hospital of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, First Hospital of Shanxi Medical University","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/stcltm\/szac015","article-title":"Current status and perspectives of allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia","volume":"11","author":"Sophie","year":"2022","journal-title":"Stem Cells Transl Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2018.09.005","article-title":"Is the overall survival for older adults with AML finally improving","volume":"31","author":"Lancet","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3322\/caac.21873","article-title":"Acute myeloid leukemia management and research in 2025","volume":"75","author":"Kantarjian","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(15)00148-9","article-title":"Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis","volume":"2","author":"Versluis","year":"2015","journal-title":"Lancet Haematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2018.08.006","article-title":"Maintenance therapy in acute myeloid leukemia: What is the future","volume":"56","author":"McMahon","year":"2019","journal-title":"Semin Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199504000-00005","article-title":"Intensive consolidation chemotherapy for newly diagnosed acute myeloid leukemia using a regime containing moderate dose cytosine arabinoside and mitoxantrone","volume":"6","author":"Liang","year":"1995","journal-title":"Anticancer Drugs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/s0889-8588(18)30258-2","article-title":"The approach to the elderly patient with acute myeloid leukemia","volume":"7","author":"Stone","year":"1993","journal-title":"Hematol Oncol Clin North Am"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1990.8.2.272","article-title":"Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly","volume":"8","author":"Tilly","year":"1990","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3109\/10428199409114151","article-title":"Delayed commencement of granulocyte colony-stimulating factor following autologous bone marrow transplantation accelerates neutrophil recovery and is cost-effective","volume":"16","author":"Clark","year":"1994","journal-title":"Leuk Lymphoma"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10185","article-title":"Recombinant granulocyte-colony stimulating factor as treatment for poor prognosis oligoblastic acute myeloid leukemia in elderly patients","volume":"92","author":"Pelizzari","year":"2007","journal-title":"Haematologica"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v93.9.2798","article-title":"Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy","volume":"93","author":"Somlo","year":"1999","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-023-02465-0","article-title":"Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology","volume":"29","author":"Maeda","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006166","article-title":"Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy","volume":"6","author":"Versluis","year":"2022","journal-title":"Blood Adv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.06.032","article-title":"Outcomes of allogeneic hematopoietic stem cell transplantation in elderly patients with myeloid Malignancies over 70 years old: a retrospective analysis of the Japanese nationwide registry","volume":"31","author":"Kobayashi","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.5966\/sctm.2014-0151","article-title":"Concise review: umbilical cord blood transplantation: past, present, and future","volume":"3","author":"Munoz","year":"2014","journal-title":"Stem Cells Transl Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/sctm.20-0495","article-title":"Umbilical cord blood transplantation: Still growing and improving","volume":"10","author":"Zhu","year":"2021","journal-title":"Stem Cells Transl Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705994","article-title":"Umbilical cord blood transplantation in adult myeloid leukemia","volume":"41","author":"Tse","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"B18","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41392-024-02065-y","article-title":"A phase 2 pilot study of umbilical cord blood infusion as an adjuvant consolidation therapy in elderly patients with acute myeloid leukemia","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1159\/000531628","article-title":"Acute myeloid leukemia treatment in the elderly: a comprehensive review of the present and future","volume":"146","author":"Choi","year":"2023","journal-title":"Acta Haematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1534158","article-title":"Prognostic impact of initial platelet count and post-induction platelet recovery in elderly AML patients: associated with circulating cytokines","volume":"15","author":"Ling","year":"2025","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-07126-y","article-title":"A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia","volume":"30","author":"Zhu","year":"2022","journal-title":"Support Care Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2024.103466","article-title":"Feasibility of co-transplantation of umbilical cord blood and third-party mesenchymal stromal cells after (non)myeloablative conditioning in patients with hematological Malignancies","volume":"72","author":"Planken","year":"2024","journal-title":"Curr Res Transl Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2022.102674","article-title":"Generation and characterization of human umbilical cord blood-derived induced pluripotent stem cells (KRIBBi005-A)","volume":"60","author":"Koh","year":"2022","journal-title":"Stem Cell Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07883.x","article-title":"Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors","volume":"147","author":"Rocha","year":"2009","journal-title":"Br J Haematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1684\/bdc.2009.1021","article-title":"Allogeneic cord blood transplantation for adults: current results and future development","volume":"97","author":"Labussiere","year":"2010","journal-title":"Bull Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1390235","article-title":"Consolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission","volume":"59","author":"Li","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.exphem.2021.11.003","article-title":"Immune composition and its association with hematologic recovery after chemotherapeutic injury in acute myeloid leukemia","volume":"105","author":"Kenswil","year":"2022","journal-title":"Exp Hematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705711","article-title":"Indiscernible benefit of high-resolution HLA typing in improving long-term clinical outcome of unrelated umbilical cord blood transplant","volume":"40","author":"Liao","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"B30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.trim.2007.11.002","article-title":"The phenotypical and functional characteristics of cord blood monocytes and CD14(-\/low)\/CD16(+) dendritic cells can be relevant to the development of cellular immune responses after transplantation","volume":"19","author":"Morgado","year":"2008","journal-title":"Transpl Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00329","article-title":"Umbilical cord blood natural killer cells, their characteristics, and potential clinical applications","volume":"8","author":"Sarvaria","year":"2017","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1186\/s12885-019-5975-8","article-title":"Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study","volume":"19","author":"Li","year":"2019","journal-title":"BMC Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031741","article-title":"Reconstruction of hematopoietic inductive microenvironment after transplantation of VCAM-1-modified human umbilical cord blood stromal cells","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS One"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.7534\/j.issn.1009-2137.2014.05.044","article-title":"Extracellular HMGB1 promotes the migration of cord blood CD34+ cells via SDF-1\/CXCR-4 axis","volume":"22","author":"Yang","year":"2014","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1867070\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:52:46Z","timestamp":1787719966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1867070\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":34,"alternative-id":["10.3389\/fonc.2026.1867070"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1867070","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1867070"}}